

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of December 2019

(Commission File No. 001-38215)

---

**NUCANA PLC**

(Translation of registrant's name into English)

---

3 Lochside Way  
Edinburgh EH12 9DT  
United Kingdom  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

---

---

---

**Other Events**

On November 13, 2019, NuCana plc (the “Company”) announced that it was prioritizing resources on its two key programs, Acelarin in biliary tract cancer and NUC-3373 in colorectal cancer. Further to that announcement, the Company has determined not to proceed with Part II of its PRO-105 study. PRO-105 is the Company’s Phase II study of single-agent Acelarin for patients with platinum-resistant ovarian cancer and had a two-part design. Part I was designed to compare a 500mg/m<sup>2</sup> dose of Acelarin versus a 750mg/m<sup>2</sup> dose of Acelarin in platinum resistant ovarian cancer in heavily pre-treated patients (patients who have received at least 3 prior lines of chemotherapy). Part II was designed to then investigate the optimal dose identified in Part I in an expansion cohort. The Company expects to report data from Part I of the PRO-105 study in the first half of 2020.

The information above shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Number 333-227624) and Form S-8 (File Number 333-223476), and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NuCana plc**

By: /s/ Donald Munoz

Name: Donald Munoz

Title: Chief Financial Officer

Date: December 27, 2019